GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
111 hedge funds and large institutions have $266M invested in GenMark Diagnostics, Inc in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 49 increasing their positions, 28 reducing their positions, and 9 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 28
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
3.31% more ownership
Funds ownership: 91.85% → 95.16% (+3.3%)
1% more funds holding
Funds holding: 110 → 111 (+1)
17% less capital invested
Capital invested by funds: $320M → $266M (-$53.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.79M |
| 2 |
NIM
Needham Investment Management
New York
|
+$3.01M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$2.35M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.04M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.89M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$2.49M |
| 3 |
Millennium Management
New York
|
-$1.86M |
| 4 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$1.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.13M |
GNMK Hedge Fund Activity: Q4 2019 in Review
111 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q4 2019, worth a combined $266M — down 17% from $320M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GNMK positions and 9 closed out — a net gain of 1 holder — while 49 added to existing stakes and 28 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.79M. The largest seller was T. Rowe Price Associates, cutting an estimated $4.89M.
- 111 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q4 2019, up from 110 in Q3 2019.
- Funds reported $266M of GenMark Diagnostics, Inc stock for Q4 2019, down 17% quarter-over-quarter.
- 10 funds opened new GenMark Diagnostics, Inc positions in Q4 2019 and 9 closed out, a net change of +1 holder.
- The largest GenMark Diagnostics, Inc buyer in Q4 2019 was Morgan Stanley, an estimated $5.79M added.
- The largest GenMark Diagnostics, Inc seller in Q4 2019 was T. Rowe Price Associates, an estimated $4.89M sold.
Based on aggregated 13F filings for Q4 2019.